Fulminant hepatic failure necessitating transplantation following the initiation of infliximab therapy: a cautionary tale times two.

@article{Rowe2013FulminantHF,
  title={Fulminant hepatic failure necessitating transplantation following the initiation of infliximab therapy: a cautionary tale times two.},
  author={Bradley W Rowe and Boris Luis Gala-L{\'o}pez and Corey Tomlinson and Safwat Girgis and James Andrew Mark Shapiro},
  journal={Transplant international : official journal of the European Society for Organ Transplantation},
  year={2013},
  volume={26 12},
  pages={e110-2}
}
Dear Sirs, Infliximab (IFX) is a human-murine chimeric antibody with well-established efficacy in the treatment for several autoimmune diseases [1,2]. However, it is known to be hepatotoxic [3–6]. While the appreciation of IFX-associated liver disease is increasing, only one other documented case of IFX-related liver failure has been reported [7]. We herein report two patients with fulminant hepatic failure temporally linked to initiation of IFX, which likely precipitated a need for urgent… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS